We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insulet Rides on Innovation, Omnipod's Wider Market Appeal
Read MoreHide Full Article
On Dec 16, we updated a research report on Insulet Corporation (PODD - Free Report) . Although the company’s achievement of two milestones with respect to expansion of Omnipod’s market reach makes us optimistic, a tough competitive landscape raises a concern. The stock carries a Zacks Rank #3 (Hold).
Shares of this leading developer, manufacturer and marketer of the Omnipod Insulin Management System have been outperforming its industry over the past three months. The stock has rallied 13.9% compared with the industry’s 1.2% rise.
Insulet exited the third quarter with better-than-expected numbers. The company witnessed a year-over-year improvement in revenues on the solid uptake of Omnipod system in the United States and overseas. Pod production at the U.S. manufacturing facility and the commercial launch of the Omnipod DASH system in the United States drove the quarterly revenues.
The recent FDA clearance of the Alternate Controller Enabled (ACE) Infusion Pump is impressive. We are also upbeat about the completion of the full-market commercial rollout of the Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System. Moreover, the company’s upped 2019 guidance and its announcement for being on track already to meet the 2021 financial targets buoy hopes on the stock.
Insulet attained several landmarks with regard to extending Omnipod’s market access. In the third quarter, the company successfully broadened the Omnipod DASH coverage for commercial, Medicare and Medicaid beneficiaries. By the end of the period, the reach was wider covering above 50% of all Medicare beneficiaries.
Further, Insulet is effectively utilizing its pay-as-you-go model and the pharmacy channel for greater market access. Through these efforts, Omnipod DASH is available with zero upfront cost. This implies higher patient base for Omnipod DASH. Per the company, since the DASH launch, a record number of new users adopted Omnipod in the United States.
Meanwhile, Insulet operates in a highly competitive environment, dominated by firms ranging from large multinational corporations with significant resources at disposal to start-ups. Also, the stiff rivalry and regulatory conditions prevalent in the markets where Insulet operates limit its ability to switch to strategies like price increases. The company’s Omnipod System primarily contests with Medtronic plc’s (MDT) market-leading MiniMed system.
Moreover, the company is exposed to risks associated with a weaker global economy and lower reimbursement rates.
Haemonetics has a projected long-term earnings growth rate of 13.5%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate of 12.9%.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
Insulet Rides on Innovation, Omnipod's Wider Market Appeal
On Dec 16, we updated a research report on Insulet Corporation (PODD - Free Report) . Although the company’s achievement of two milestones with respect to expansion of Omnipod’s market reach makes us optimistic, a tough competitive landscape raises a concern. The stock carries a Zacks Rank #3 (Hold).
Shares of this leading developer, manufacturer and marketer of the Omnipod Insulin Management System have been outperforming its industry over the past three months. The stock has rallied 13.9% compared with the industry’s 1.2% rise.
Insulet exited the third quarter with better-than-expected numbers. The company witnessed a year-over-year improvement in revenues on the solid uptake of Omnipod system in the United States and overseas. Pod production at the U.S. manufacturing facility and the commercial launch of the Omnipod DASH system in the United States drove the quarterly revenues.
Insulet Corporation Price
Insulet Corporation price | Insulet Corporation Quote
The recent FDA clearance of the Alternate Controller Enabled (ACE) Infusion Pump is impressive. We are also upbeat about the completion of the full-market commercial rollout of the Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System. Moreover, the company’s upped 2019 guidance and its announcement for being on track already to meet the 2021 financial targets buoy hopes on the stock.
Insulet attained several landmarks with regard to extending Omnipod’s market access. In the third quarter, the company successfully broadened the Omnipod DASH coverage for commercial, Medicare and Medicaid beneficiaries. By the end of the period, the reach was wider covering above 50% of all Medicare beneficiaries.
Further, Insulet is effectively utilizing its pay-as-you-go model and the pharmacy channel for greater market access. Through these efforts, Omnipod DASH is available with zero upfront cost. This implies higher patient base for Omnipod DASH. Per the company, since the DASH launch, a record number of new users adopted Omnipod in the United States.
Meanwhile, Insulet operates in a highly competitive environment, dominated by firms ranging from large multinational corporations with significant resources at disposal to start-ups. Also, the stiff rivalry and regulatory conditions prevalent in the markets where Insulet operates limit its ability to switch to strategies like price increases. The company’s Omnipod System primarily contests with Medtronic plc’s (MDT) market-leading MiniMed system.
Moreover, the company is exposed to risks associated with a weaker global economy and lower reimbursement rates.
Key Picks
A few better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , NuVasive, Inc and ResMed (RMD - Free Report) . While ResMed flaunts a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics has a projected long-term earnings growth rate of 13.5%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate of 12.9%.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>